Key Highlights

  • Third US civilian blood Partnership secured with Versiti Blood Health, adding to Vitalant and Hoxworth Blood Center, covering approximately 17% of US civilian blood collection sites
  • Entered the US cell and gene therapy market through an agreement with Charter Medical, expanding beyond blood collection
  • Scientific Advisory Board established with leaders in transfusion medicine, cell therapy and clinical research
  • Ended Q1 FY27 with A$38.3 million in cash and term deposits as at 30 September 2026, debt-free

Three Partnerships and a New Market Segment

Vitrafy Life Sciences Limited (ASX:VFY), an Australian developer of cryopreservation technology, has delivered a quarterly activities report for Q1 FY27 that maps out a meaningfully expanded commercial footprint in the United States. The period ended 30 September 2026 saw the company secure its third US civilian blood partnership, enter the cell and gene therapy market, and advance preparations for US FDA medical device listing.

The third blood partnership, announced on 30 September 2026, was with Versiti Blood Health, a blood research organisation based in Milwaukee. Vitrafy will initially place two of its Guardion cryopreservation devices at Versiti's Blood Research Institute to advance development of no-wash platelet cryopreservation. Versiti will also Supply blood products to support Vitrafy's validation studies of currently approved cryopreserved blood products including plasma, as part of the FDA device listing process.

The three partnerships — Vitalant, Hoxworth Blood Center, and Versiti — together provide exposure to approximately 17% of total US civilian blood collection sites, covering approximately 179 fixed-point collection sites that together collect approximately 2.4 million units of blood annually.

Cell and Gene Therapy: A New Avenue

Beyond blood banking, Vitrafy disclosed an agreement with Charter Medical to enter the US cell and gene therapy market. This moves the company's addressable market well beyond conventional blood collection into a sector with its own significant unmet preservation needs. Cell and gene therapy products are notoriously sensitive to storage and transport conditions, and cryopreservation technology that can address those challenges carries substantial commercial potential.

Managing Director and CEO Brent Owens described the quarter as a clear step up in pace, noting that the company's cryopreservation ecosystem is increasingly being recognised as addressing a persistent problem around the limited availability of life-saving biological products when they are needed most. He said the company's priorities remain on completing verification and validation work for the FDA medical device listing, building US Manufacturing capacity, and supporting partner deployments of pre-commercial devices.

Leadership Additions and Scientific Advisory Board

The quarter also saw Vitrafy strengthen its operational infrastructure. The company added an experienced Chief Operating Officer and Chief Financial Officer, providing the management depth typically needed to execute a multi-partner commercial rollout. A Scientific Advisory Board was also established, comprising leaders in transfusion medicine, cell therapy, and clinical research, to guide the company's path toward clinical adoption.

Sector Context

The global blood management market faces a persistent tension between supply and Demand for stored blood products. Cryopreservation extends the shelf life of red blood cells and platelets significantly beyond conventional refrigeration storage — a meaningful advantage for blood banks managing inventory across large geographic footprints or preparing for surge demand scenarios. The US market, with its complex network of regional and national blood collectors, is the most commercially significant globally.

Regulatory approval from the FDA for the Guardion device would open formal commercial sales channels beyond the current pre-commercial partnership model. The company has indicated FDA medical device listing remains on track for late 2026, making that an imminent catalyst.

Risks

Vitrafy remains in a pre-revenue phase, with commercial activity contingent on completing the FDA listing process. Delays to that listing would push back the timeline for partner deployments from pre-commercial to commercial status. The company is also operating across multiple partnership relationships simultaneously, each requiring technical and logistical coordination. Cash of A$38.3 million provides meaningful runway, but ongoing operating cash outflows will need to be managed relative to the commercial timeline.

What to Watch Next

The FDA medical device listing decision for the Guardion device, targeted for late 2026, is the immediate near-term trigger. Following that, the conversion of pre-commercial partner deployments into commercial agreements will be the key revenue-generating milestone. Any further partnership announcements in the cell and gene therapy space, or updates on Versiti's platelet cryopreservation development work, would also be material to the Investment case.